Similarly, OSU-T315, an inhibitor of integrin-linked kinase, was observed to inhibit Mcl-1 expression levels via targeting the GSK-3β/FBXW7 axis in bladder cancer cells (140). Here, MCL1 is linked to urinary bladder carcinoma.